|
Test ID: Beta 2 Glycoprotein IgG/IgM
|
|
Beta 2 Glycoprotein IgG/IgM
|
|
|
|
Useful For
|
Evaluation of the patient with suspected antiphospholipid syndrome (APS) and to evaluate the thrombotic risk in patients with systemic lupus erythematosus (SLE) by measurement of IgG and IgM antibodies directed to cardiolipin in human serum.
|
|
Method name and description
|
Method: Fluorescence Enzyme Immunoassay (FEIA). Uses the EliA method on Phadia system.
Using EliA technology solid phase, analyte molecules can be extracted from a sample. To achieve this, a well is coated with an antigen that specifically binds to target antibodies. Following the removal of non-bound antibodies, enzyme-labeled antibodies against human antibodies (EliA Conjugate) are added to form an antibody conjugate complex. This complex is then incubated and non-bound conjugate is subsequently washed away. The bound complex is then incubated with a Development Solution, and after stopping the reaction, the fluorescence in the reaction mixture is measured. A higher response value indicates the presence of a more specific antibody in the specimen.
|
|
Reporting name
|
Beta 2 Glycoprotein IgG/IgM
Anti B2 Glycoprotein IgG
Anti B2 Glycoprotein IgM
|
|
Clinical information
|
Anti-cardiolipin antibodies (ACA) belong to the group of anti-phospholipid antibodies (aPL). Their occurrence was first demonstrated in sera of syphilis patients, but later they have also been described frequently in SLE (systemic lupus erythematosus) patients (prevalence 30-40%) and in patients with other rheumatic diseases. The antiphospholipid syndrome (APS), also known as “Hughes syndrome”, is characterized by typical clinical features such as arterial/venous thromboses or recurrent miscarriages together with persistently positive tests for aPL. In contrast to “secondary APS” which occurs in association with SLE or other rheumatic disorders, there is no evidence for another relevant underlying disease in primary APS.
antiphospholipid antibodies (ACA) / lupus anticoagulant (LA) are considered to be of significant diagnostic relevance, as a correlation has been found between these antibodies and a tendency towards thromboses. This results in an increased incidence of venous/arterial thromboses (including apoplexy), thrombocytopenia, livedo reticularis, habitual abortion and neurological manifestations in ACA/LA positive patients. Elevated levels of ACA/LA may also be found in patients with cerebrovascular insufficiency or myocardial infarction.
|
|
Aliases
|
Beta 2 Glycoprotein IgG/IgM
β2-Glycoprotein I IgG Antibodies
β2-Glycoprotein I IgM Antibodies
Beta-2 Glycoprotein 1
B2 IgG
B2 IgM
|
|
|
Specimen type / Specimen volume / Specimen container
|
Specimen type: Serum sample.
Specimen Volume: At minimum 2 mL whole blood or 0.5 mL serum.
Container Tube: Plan tube /Serum gel (Yellow top tubes).
|
|
Storage and transport instructions
|
For sample transportation, the sample should remain at room temperature (18-25°C) for no longer than eight hours.
Separated serum samples can be stored at 2-8°C for one week.
Separated serum samples should be frozen at below -20°C for any long-term storage.
|
|
Specimen Rejection Criteria
|
Quantity not sufficient (QNS)
Hemolysis
Lipemic
Wrong collection container
|
|
|
Biological reference intervals and clinical decision values
|
β2-Glycoprotein I, IgG:
| Interpretation of Test Results |
Reference Values (U/ml) |
| Negative |
< 7 |
| Equivocal |
7 - 10 |
| Positive |
> 10 |
β2-Glycoprotein I, IgM:
| Interpretation of Test Results |
Reference Values (U/ml) |
| Negative |
< 7 |
| Equivocal |
7 - 10 |
| Positive |
> 10 |
|
|
Turnaround time / Days and times test performed / Specimen retention time
|
Turnaround Time: 5 working days.
Days and Times tests are performed: Twice a week starting from Sunday through Thursday from 7:00 to 15:00.
Specimen retention time: Approximately 14 days.
|
|
|
